The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA
Jonathan Ledermann, MD, FRCP, University College London, London, UK, discusses three Phase III clinical trials exploring the potential of PARP…
Related Articles
Real-world impact of bevacizumab with pembrolizumab in cervical cancer
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)
The future of HER2-directed therapies in non-small cell lung cancer
Joshua Sabari, MD, New York University Langone Health, New York, NY, provides an overview of the growing options in the HER2 space for non-small cell…
Utilizing midkines to improve outcomes in SCLC and MCC
Curtis Perry, MD, PhD, Yale University, New Haven, CT, describes the benefits of identifying midkines in immune resistant Merkel cell carcinoma (MCC) and small cell…
Improving early clinical trial enrolment in pediatric oncology
Lesleigh Abbott, MD, The Children’s Hospital of Eastern Ontario, Ottawa, Canada, gives an overview of barriers to early-phase clinical trial enrolment for pediatric patients with…
Reforming the treatment landscape in melanoma with T-cell therapies
Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, shares his insight into the emerging T-cell therapies for patients with melanoma and their impact…
Evaluating fianlimab and cemiplimab in PD-L1+ recurrent/metastatic HNSCC
Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, describes the design of a Phase II trial (NCT06769698) of fianlimab plus cemiplimab versus cemiplimab plus…
Important considerations in developing CAR-T cell therapy for GBM
Reena Thomas, MD, PhD, Stanford University, Stanford, CA, comments on the importance of managing on-target tumor-associated inflammatory neurologic impacts in patients with glioblastoma (GBM). The…
How will ctDNA and liquid biopsies be utilized in gynecological cancers?
Jyoti Mayadev, MD, University of California San Diego Medical Center, San Diego, CA, discusses the emerging developments in liquid biopsies and circulating tumor DNA (ctDNA)…
Welcome! You are invited to join a webinar: Post-ASCO 2025 Skin Cancer Highlights. After registering, you will receive a confirmation email about joining the webinar.
Virtual webinar hosted by VJOncology featuring presentations & discussions on selected abstracts in skin cancer from ASCO 2025. Chaired by Dr Meredith McKean Moderated by…
Post-ASCO 2025 Breast Cancer Highlights Archives – VJOncology
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our…